Day: May 12, 2021

Checkpoint Therapeutics Announces Completion of Enrollment in the Registration-Enabling Trial of Cosibelimab in Metastatic Cutaneous Squamous Cell Carcinoma

Top-line results expected in 4Q 2021Targeting BLA submission in 1H 2022Market-disruptive pricing planned in $25 billion and growing PD-(L)1 marketNEW...

error: Content is protected !!